Main Reasons for Registration Application Refusal of Generic and Similar Pharmaceutical Drug Products by the Brazilian Health Regulatory Agency (ANVISA)

Abstract

Objective. The marketing authorization of generic and similar pharmaceutical drug products involves the analysis of proposing company's administrative aspects as well as drug product technical description and scientific evaluations. This study evaluated the main reasons for registration refusal of generic and similar pharmaceutical drug products in Brazil. The aim is to help future applicants to better organize the proposal. Methods. A retrospective search of drug products registration processes was performed on the Brazilian Government Official Gazette from January 1, 2015, and December 31, 2015. Results. Drug product quality control, drug product stability study, deadline accomplishment, API quality control made by drug manufacturer, active pharmaceutical ingredient (API), and production report were the main reasons for marketing authorization application refusal of generic and similar pharmaceutical drug products in 2015. Conclusion. Disclosure of the reasons behind failed applications is a step forward on regulatory transparency. Sharing of experiences is essential to international regulatory authorities and organizations to improve legislation requirements for the marketing authorization of generic and similar pharmaceutical drug products.

Quality of medicines: Deficiencies found by Brazilian Health Regulatory Agency (ANVISA) on good manufacturing practices international inspections

“…ANVISA has also been shown to refuse a large number of MA when compared to the U.S. FDA and EMA, with drug product quality control, drug product stability study, active pharmaceutical ingredient quality control made by drug manufacturer, active pharmaceutical ingredient and production report being the main technical reasons for MA refusal in 2015 [ 38 ]. These issues are also part of GMP inspections and may reflect on GMP compliance since the most cited deficiency found by ANVISA refers to products not consistently produced and controlled according to the quality standards appropriate to their intended use and as required by the marketing authorization (Art.…”

Development of USP Apparatus 3 Dissolution Method with IVIVC for Extended Release Tablets of Metformin Hydrochloride and Development of a Generic Formulation

“…The Brazilian Health Surveillance Agency (ANVISA) accepts registrations of pharmaceutical products in one of the three types, either reference, generic or similar. 12,13) In Vitro-in Vivo Correlation The IVIVC study was performed with data from the in vitro dissolution profiles of Glifage ® XR tablets and the in vivo plasma concentration data of the drug after oral administration in fasting individuals obtained from previously reported pharmacokinetic studies. [14][15][16] The absorbed fraction (% Fa) of MTF was calculated by mathematical deconvolution of the in vivo absorption data using the mathematical equation of Loo-Riegelman (Eq.…”